natgillin/translations-raw huggingface dataset:
Yet another preferred embodiment of the present invention is the compound of formula (I) wherein R4 is indazolyl, benzoimidazolyl, 1-oxo-1,2-dihydroisoquinolinyl, 1H-pyrrolo[3,2-b]pyridinyl, 2-oxo-2,3-dihydro-1H-benzo[d]imidazolyl, 1H-pyrazolylphenyl, 1H-pyrazolylpyridinyl, or 1H-imidazolylphenyl; each optionally substituted with one to two methyl, chloro or fluoro; or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 4, naznačen time što je R* indazolil, benzoimidazolil, 1-okso-1,2-dihidroizokinolinil, 1H-pirolo[3,2-b]piridinil, 2-okso-2,3-dihidro-177-benzo[dlimidazolil, 17-pirazolilfenil, 1H- pirazolilpiridinil ili 127-imidazolilfenil; od kojih je svaki izborno supstituiran s jednim do dva metila, klora ili fluora; ili njegova farmaceutski prihvatljiva sol.
The apparatus of claim 8, wherein said supercritical fluid supply device further comprises a control valve for controlling pressure and flow rate of said supercritical fluid. 
Uređaj u skladu s patentnim zahtjevom 8, naznačen time što navedeni uređaj za dobavu superkritičnog fluida dodatno sadrži kontrolni ventil, radi kontroliranja tlaka i brzine protoka navedenog superkritičnog fluida.
A compound according to claim 1, wherein the compound is of formula IIA, IIB or IIC 
HR P20191189 T1 PATENTNI ZAHTJEVI 1. = Spoj je formule IIA, formule IIB ili formule IIC
The composition of claim 11 wherein the organic compound contains a rare earth element, preferably gadolinium. 
Smjosa iz patentnog zahtjeva 11, naznačena time, da organski spoj sadrži clement rijetke zemlje, poželjno jo gadolinij.
An apparatus (2000) for entropy decoding transformation coefficients, the apparatus comprising an entropy decoder configured to: extract information about a horizontal axis direction location and a vertical axis direction location of a last significant transformation coefficient having a non-zero value and included in a transformation block, from a received bitstream wherein the last significant transformation coefficient has last scan index according to a certain scan order among the transformation coefficients, 
kada indikator kodiranog bloka pokazuje postojanje najmanje jednog značajnog koeficijenta u transformacijskom bloku, izvlačenje (1910) informacija o lokaciji smjera vodoravne osi i lokaciji smjera okomite osi zadnjeg značajnog koeficijenta transformacije koji ima vrijednost različitu od nula i nalazi se u transformacijskom bloku, iz primljenog toka bitova naznačen time da zadnji značajni koeficijent transformacije ima zadnji indeks skeniranja prema određenom redoslijedu skeniranja između koeficijenata transformacije;
In a second further embodiment of the invention, step b) is carried out with a solution having an acidic pH, preferably between about 3 and 6.8. 
Prema drugoj dodatnoj izvedbi izuma, korak b) se provodi otopinom sa kiselim pH, poželjno između otprilike 3 1 6.8.
The method according to claim 13, wherein said agent is SOCl2. 
Postupak prema zahtjevu 13, gdje je to sredstvo SOC.
from 0.1 to 5% by dry weight of an extract of Citrus species, 
- od 0,1 do 5% suhe mase ekstrakta Citrus vrsta,
A package as claimed in any one of Claims 1 to 8, and comprising a rigid outer container (2) housing the inner package (3). 
Pakiranje u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačeno time, da sadrži čvrsti vanjski spremnik (2) u koji se stavlja unutarnje pakiranje (3).
For these parts, a Class A surface is required. 
Za te dijelove, traži se površinu razreda A.
A compound of formula (I) or a pharmaceutically acceptable salt or a pharmaceutically acceptable regioisomer thereof, wherein; 
Spoj formule (I) ili farmaceutski prihvatljiva sol istog, pri čemu;
The lock according to claim 11, wherein the cross section of the radial projections of the tumbler discs have two substantially parallel side lines directed vertically in relation to the plane of the tumbler discs, which, at both ends, change to a bevel, the bevel angle and extension of which are fitted for contact and axial force transfer on an oblique travelling part of the guide groove of key. 
(31) od diskova za zadržavanje, ima dvije uglavnom paralelne bočne linije (35) usmjerene vertikalno u odnosu na ravninu diskova za zadržavanje, koje na svoja oba kraja mijenjaju nagib (33), kut nagiba i protezanje, s kojima su podešeni za kontakt i prijenos aksijalne sile na nepravocrtno putujući dio od upravljačkog utora (15a, 15b) ključa. .
In another embodiment, the compound is selected from the group consisting of: 
Spoj prema zahtjevu 1, izabran iz skupine koju čine:
The antibody, or an antigen binding fragment thereof of claim 1, comprising a heavy chain having at least 95% sequence identity to SEQ ID NO: 9 wherein said antibody binds to human complement C5 protein. 
Nukleinska kiselina prema zahtjevu 10, naznačena time, da obuhvaća nukleotidnu sekvencu koja kodira polipeptid koji ima vrijabilno područje jakog lanca s najmanje 95% identiteta sekvence prema SEQ ID NO:7, ili varijabilno područje slabog lanca s najmanje 95% identiteta sekvence prema SEQ ID NO:8.
The method of claim 1, wherein the reperfusion therapy is performed after determining the primate qualifies for reperfusion based on lack of a completed infarction, an ischemic penumbra and lack of hemorrhage as shown by CT, MRI or PET analysis. The method of claim 20, wherein the reperfusion therapy is performed at least 12 or at least 24 hours after onset of ischemia. 
Inhibitor PSD-95, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što se reperfuzijsku terapiju provodi najmanje 12 ili najmanje 24 sata nakon početka ishemije, 1li što se reperfuzijsku terapiju provodi 275-690 minuta nakon početka ishemije.
to form a composition; shaping the composition to form an extended release matrix formulation; and curing said extended release matrix formulation comprising at least a curing step of subjecting the extended release matrix formulation to a temperature which is at least the softening temperature of said polyethylene oxide for a time period of at least 5 minutes. 
Oblik za doziranje s produljenim otpuštanjem prema bilo kojem zahtjevu od 1 do 23, koji je u obliku tablete napravljene izravnim komprimiranjem sastojka i sušen najmanje podvrgavanjem navedene tablete na temperaturu od barem oko 60°C ili od barem oko 62°C, u vremenskom razdoblju od barem oko 1 minute, poželjno od barem oko 5 minuta ili od barem oko 15 minuta.
The system of claim 6, including multiple said current transformer electrical connectors removably connectible into the switchboard (100, 100a) for removably connecting the device to a variety of electrical supplies at the switchboard of the building or installation. 
Sustav prema zahtjevu 6, koji uključuje više električnih konektora za strujne transformatore, gdje se ti konektori mogu spojiti i otspojiti od razvodne ploče (100, 1004) u svrhu spajanja i odspajanja uređaja s mnoštvom različitih izvora napajanja na razvodnoj ploči zgrade ili postrojenja.
However, the essentially inactive (-)-a-[11C]dihydrotetxabenazine isomer was almost uniformly distributed in the brain, suggesting that specific binding to DAT and VMAT2 was not occurring. 
Doduše, esencijalno neaktivan (-)-0, -['"C]dihidrotetrabenazin izomer je bio gotovo jednolično raspodijeljen u mozgu, ukazujući da nije došlo do specifičnog vezivanja na DAT i VMAT2.
A method according to any preceding claim wherein the disubstituted azodicarboxylate is chosen from dimethylazodicarboxylate, diethylazodicarboxylate, diisopropylazodicarboxylate, di-tert-butylazodicarboxylate and 1,1'-(azodicarbonyl)dipiperidine. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva naznačen time da je disupstituirani azodikarboksilat izabran iz dimetilazodikarboksilata, dietilazodikarboksilata, diizopropilazodikarboksilata, di-tert-butilazodikarboksilata i 1,1'-(azodikarbonil)dipiperidina.
In one embodiment, the invention relates to a composition comprising at least 99.0% by weight of trans-(−)-A9-THC; in another embodiment, at least about 99.5% by weight of trans-(−)-A9-THC; and in another embodiment, at least 99.9% by weight of trans-(−)-A9-THC based on the total amount of cannabinoids. 
Postupak prema bilo kojem od zahtjeva 7 do 10, naznačen time da (+)-A*-tetrahidrokanabinol sadrži barem 95% težinski, poželjno barem 98% težinski i poželjnije barem 99% težinski trans-(-)-A*-tetrahidrokanabinola i trans-(+)- A?-tetrahidrokanabinola u odnosu na ukupnu količinu kanabinoida.
with the proviso that when bond a is a single bond and bond b is a double bond; and X is N R1; R1 is H; and R2 is O; and 
uz uvjet da kada veza a je jednostruka veza i veza b je dvostruka veza; te X je NR1; R1 je H; te R2 je O; te
A method for preparing a foamed rigid polymer product comprising the following steps: providing the resin composition according to any one of claims 1 to 11, and subjecting the resin composition of step a) to conditions under which said resin composition is converted into a foamed rigid polymer product. 
Postupak priprave pjenastog krutog polimernog produkta koji sadrži slijedeće korake: a) pružanje smolastog sastava prema bilo kojem od zahtjeva 1 do 11,i b) podvrgavanje smolastog sastava iz koraka a) uvjetima pri kojima se spomenuti smolasti sastav pretvara u pjenasti kruti polimerni produkt.
A building comprising a plurality of prefabricated building wall panels as claimed in any one of the preceding claims. 
Zgrada koja obuhvaća više montažnih zidnih ploča sukladno bilo kojem od prethodnih zahtjeva.
a vector comprising said isolated nucleic acid operatively linked to a promoter, wherein the vector optionally further comprises nucleic acid sequences encoding at least one eod sequence, wherein the eod sequence comprises an amino acid sequence having at least 50% sequence identity to SEQ ID NO: 9 with a mutation at a position corresponding to position 44 of SEQ ID NO:9. A method of prolonging the growth period in a plant which comprises expressing DA1R358K within said plant; 
DA Â«polipeptid prema zahtjevu 9; ili vektor koji obuhvaća navedenu izoliranu nukieinsku kiselinu koja je operativno vezana na promotor, naznačen/a time, da vektor prema potrebi dodatno obuhvaća sekvence nukleinske kiseline, koje kodiraju najmanje jednu eod-sekvencu, pri čemu eod-sekvenca obuhvaća aminokiselinsku sekvencu koja ima najmanje 50% identiteta sekvence od SEQ ID N(:9, s mutacijom na poziciji koja je ekvivalentna poziciji 44 od SEQ ID NO:9.
The method of claim 3, wherein the pinanediol boronic ester has the structure of formula (XII): and optionally wherein the deprotection and cyclization comprises contacting the pinanediol boronic ester with a reagent selected from the group consisting of HCl, BCl3, BBr3, and CF3COOH. 
[image] te opcionalno pritom, uklanjanje zaštitne skupine i ciklizacija obuhvaćaju dovođenje u doticaj pinandiol estera boronske kiseline s reagensom koji je odabran iz skupine koju čine: HCl, BCl3, BBr3 i CF3COOH.
In one embodiment the invention is a compound of formula (I) wherein R is hydrogen or C(O)-R1, wherein R1 is a linear alkyl chain containing 2 to 5 carbon atoms, and wherein R' is a linear alkyl chain containing 3 to 6 carbon atoms or an optionally substituted aryl group or an optionally substituted heteroaryl group. 
naznačen time što: R je C(O)-Ry; R, je vodik ili nerazgranati alkilni lanac, koji sadrži 2 do 5 atoma ugljika; i R' je nerazgranati alkilni lanac, koji sadrži 3 do 6 atoma ugljika ili izborno supstituirana arilna skupina ili izborno supstituirana heteroarilna skupina;
Rate of animals with thrombotic occlusion (% of 
Broj životinja s tromboznom okluzijom (% zaštićenih životinja)
The method of claim 9, wherein said anti-G protein antibodies are protective. 
Postupak sukladno patentnom zahtjevu 9, naznačen time da su navedena antitijela protiv G proteina zaštitna.
The compound, a pharmaceutically acceptable salt or a hydrate thereof according to claim 1, wherein, in the formula (I), 
Spoj, farmaceutski prihvatljiva sol ili njihov hidrat temeljem zahtjeva 1, pri čemu u formuli (1),
opening of the epoxy ring of compound 3, with simultaneous removal of the chlorine atom, by reaction with acetic acid, zinc and copper bromide in 1,2-dimethoxyethane heating up to 70°C, to obtain 5-hydroxy-15B,16B-methylen-3B-pivaloyloxy-5B-androst-6-en-17-one 4: 
otvaranje epoksidnog prstena spoja 3 uz istovremeno uklanjanje atoma klora, a reakcijom s octenom kiselinom i bakrovim bromidom u 1,2-dimetoksietanu zagrijavanjem na 70°C, čime je dobiven 5-hidroksi-15B,16B-metilen-3B-pivaloiloksi-5B-androst-6-en-17-on 4:
The pharmaceutical product for use according to claim 16, wherein the tablet comprises a tablet coating comprising polyvinyl alcohol-part hydrolyzed, titanium dioxide, polyethylene glycol 3350, and talc. 
Farmaceutski proizvod za uporabu prema patentnom zahtjevu 16, naznačen time, da tableta sadrži premaz koji obuhvaća djelomično hidrolizirami polivinilni alkohol, titanijev dioksid, polietilen glikol 3350 i talk.
directing the product stream comprising beta propiolactone and the C1-8 alcohol to a second reaction zone where it is contacted with a catalyst which catalyzes the conversion of beta propiolactone and the C1-8 alcohol to the corresponding acrylic acid ester; 
usmjeravanja struje produkta koja sadrži B-propiolakton i C1-8 alkohol u drugo područje reakcije gdje dolazi u kontakt s katalizatorom koji katalizira prevođenje B-propiolaktona i C1-8 alkohola u odgovarajući ester akrilne kiseline;
A composition comprising the mutant leukocidin subunit of claim 10 and a carrier. 
kombiniranje mutantne podjedinice leukocidina ili polipeptidnog kompleksa s pomoćnim sredstvom.
wherein X1, X2, W, R1, R3 to R5, L and m have the meaning as defined above, with the proviso that the 5-pyrrolidin-1-ylmethyl-thiazol-2-ylamine is excluded. 
(IE) pri čemu XL, X2W,RL,R>toR%Lim imaju značenje kako je definirano u patentnom zahtjevu 1; pod uvjetom da je isključen 5-pirolidin-1-ilmetil-tiazol-2-ilamin.
wherein: represents —CH2OtBu or —CH(CH3)OtBu; Aaa is an amino acid residue selected from Thr and Ser; wherein the C-terminus thereof is esterified, and wherein the hydroxy moiety of the side chain of Thr or Ser is substituted with t-butyl; 
Aaa je aminokiselinski ostatak, kojeg se bira između Thr i Ser; gdje je njegov C-kraj slobodni kraj, amidiran je ili je esterificiran, te gdje je hidroksi dio bočnog lanca u Thr ili Ser supstituiran alkilom, primjerice tercijarni butil;
The residue was treated with water and the precipitate was filtered, the crude product was triturated with diethyl ether and filtered to afford 2.94g of pure product as a white solid. 
Ostatak se obradi vodom, talog filtrira, a sirovi produkt triturira dietil-eterom, te filtrira kako bi se dobilo 2,94 g čistog produkta u obliku bijele krutine.
Preferably the final moisture content of the lozenges is approximately 10%. 
Poželjno, krajni sadržaj vlage tableta je približno
The process of claim 3, wherein the suitable solvent of step a) is selected from the group consisting of acetone, methanol, ethanol, propanol, water, ethyl acetate, i-propanol, butanol, i-butanol, s-butanol, t-butanol, hexane, toluene, t-butyl-methyl ether, trichloroethane, and mixtures thereof. 
Postupak iz zahtjeva 4 gdje se prikladno otapalo iz koraka a) bira iz skupine koja se sastoji od acetona, metanola, etanola, propanola, vode, etil acetata, i-propanola, butanola, i-butanola, s-butanola, f-butanola, heksana, toluena, f- butil-metil etera i trikloretana, i njihovih smjesa.
Item 114: An antibody engineered to have increased Fc receptor binding affinity produced by the method of any one of items 102-111. 
(iti) kako bi imalo povećani afinitet vezanja Fc receptora u usporedbi prema protutijelu koje nije bilo podvrgnuto glikoinženjeringu; i
The compound of claim 1, wherein the modified oligonucleotide consists of 16 linked nucleosides having a nucleobase sequence consisting of SEQ ID NO: 9, and wherein the modified oligonucleotide comprises: 
Spoj prema patentnom zahtjevu 1, gdje se modificirani oligonukleotid sastoji od 16 povezanih nukleozida sa sekvencom nukleobaza koja čini SEQ ID NO: 9 i gdje modificirani oligonukleotid sadrži:
Ultrafiltered r-hIL-18BP post MEP (see step (b)) was brought to pH 6.0±0.2 with some drops of 20 mM MES pH 5±0.5 and conductivity 100±15 uS/cm just before being loaded on the column. 
Ultrafiltriranom r-hIL-18BP dobivenog nakon MEP-a (vidi korak (b)) podešen je pH do 6.0 £ 0.2 s nekoliko kapi 20 mM MES-a pH 5:+0.5 i provodljivosti 100 + 15 uS/em neposredno prije njegovog nanošenja na kolonu.
The beverage or liquid comestible being the result of the interaction of the introduced liquid and the ingredients contained in the capsule 27 can then be drained from the capsule 24 using draining means 27 connected to the lower frame 6. 
Napitak ili tekući prehrambeni proizvod koji su rezultat interakcije uvedene tekućine 1 sastojka koji je sadržan u čahuri 27 može tada biti odveden iz čahure 24 koristeći sredstvo za odvođenje 27 koje je spojeno na donji okvir 6.
human hematopoietic stem cells (HSCs), wherein said HSCs have a phenotype of CD34+; 
HR P20160102 T1 PATENTNI ZAHTJEVI Terapeutski stanični pripravak koji obuhvaća: humane krvotvorne matične stanice (HKMS, engl.
A compound of Claim 6 wherein R3, R4 and the carbon atom to which they are attached together form -C3-6cycloalkyl. 
Spoj prema patentnom zahtjevu 6 naznačen time što Rs, Rx i atom ugljika za koji su vezani zajedno formiraju -Ca.sCikloalkil.
The compound as set forth in (2), wherein Ring Ac is phenyl substituted with halogen. A compound selected from the group consisting of: 
Spoj ili njegova sol za uporabu prema zahtjeva 2, naznačen/a time, da Prsten A" je fenil koji je supstituiran s halogenom.
A cloning or expression vector comprising one or more isolated polynucleotide sequences according to enbodiment 27 or enbodiment 28. 
Vektor kloniranja ili ekspresije, naznačen time, da on obuhvaća jednu ili više izoliranih polinukleotidnih sekvenci u skladu sa zahtjevom 12 ili zahtjevom 13.
The solid oral pharmaceutical formulation of claim 1, wherein the formulation is a capsule selected from the group consisting of: 
Kruta oralna farmaceutska formulacija prema zahtjevu 1, naznačena time što je formulacija kapsula odabrana iz skupine koja sadrži: A)
The benefits of the present light stabilising composition are particularly pronounced if said composition is used to stabilise bottled beverages. 
Prednosti sadašnjeg pripravka za stabiliziranje na svjetlo su naročito izražene ako se spomenuti pripravak upotrebljava za stabiliziranje flaširanih pića.
The antibody, conjugate or pharmaceutical composition for use according to claim 6 wherein the disease or disorder is a tumor-related disease, wherein the tumor-related disease preferably is selected from the group consisting of breast cancer, gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, colorectal cancer, hepatic cancer, head-neck cancer, cancer of the gallbladder, and the metastases thereof. 
Protutijelo, konjugat ili farmaceutski pripravak za uporabu sukladno patentnom zahtjevu 6 naznačeno time, što bolest ili poremećaj je bolest povezana s tumorom, pri čemu je bolest povezana s tumorom poželjno odabrana iz skupine koja se sastoji od karcinoma dojke, karcinoma želuca, karcinoma jednjaka, karcinoma pankreasa, karcinoma pluća, karcinoma jajnika, karcinoma debelog crijeva, kolorektalnog karcinoma, karcinoma jetre, karcinoma glave-vrata, karcinoma žučne vrećice i njihovih metastaza.
Furthermore, they keep the particles apart and allow them to glide past each other. 
Nadalje, drži čestice razdvojenima i omogućava da klize jedne po drugima.
represents an indanyl or tetralinyl group substituted or not by one or more groups selected from halogen atoms, alkyl groups, hydroxy, alkoxy groups, amino, mono- or di-alkylamino groups, carboxy groups, alkyloxycarbonyl groups, mono- or di-alkylaminocarbonyl groups, carboxamide, cyano, alkylsulfonyl and trifluoromethyl groups; 
predstavlja indanil ili tetralinil skupinu supstituiranu ili ne s jednim ili više skupina odabranih između atoma halogena, alkil skupina, hidroksi, alkoksi skupina, amino, mono- ili di-alkilamino skupina, karboksi skupina, alkiloksikarbonil skupina, mono- ili di-alkilaminokarbonil skupina, karboksamida, cijano, alkilsulfonil i trifluorometil skupina;
a control unit operably controlling the operation of the device adapted to produce the sodium hypochlorite or hypochlorous acid; 
upravljačku jedinicu (80) za upravljanje radom navedenog uređaja (40).
Soluble, non selective, non digestible oligosaccharide 
15 Topljivi, neselektivni, neprobavljivi oligosaharid
the compound of formula (VI) is subjected to a basic hydrolysis reaction in order to obtain the compound of formula (VII): 
spoj s formulom (VI) se podvrgava bazičnoj reakciji hidrolize kako bi se dobilo spoj s formulom (VII): [image]
When the sheets 6 and 7 as well as the filling layer 8 are laminated together, the sheets 6 and 7 are also laminated together at the apertures 9. 
Kada se listovi 6 i 7 kao i sloj za ispunu 8 zajedno spoje, listovi 6 i 7 se također zajedno spoje kod otvora 9.
The process according to claim 1, wherein the water-soluble compound is a saccharide with one to five monose units. 
Postupak sukladno Zahtjevu 1, pri čemu je otopina topiva u vodi saharid s jednom do pet jedinica manoze.
The crude enamine was added to a mixture of glacial acetic acid (5 ml.), sodium borohydride (1.3 g., 0.034 mole) and tetrahydrofuran (50 ml.), and the resulting mixture stirred for 3 hours at room temperature. 
Sirovi enamin se doda na smjesu glacijalne octene kiseline (5 mil), natrij-borhidrida (1.3 g., 0.034 mola) i tetrahidrofurana (50 ml.), i dobivena smjesa se miješa 3 sata na sobnoj temperaturi.
seeding the solution with crystalline form II of N -benzoyl-staurosporine; and 
(b) kultiviranje otopine s kristalnim oblikom II od N-benzoil-staurosporina;
The process according to claim 7, characterized in that heat treatment of the feed mixture, which contains the fatty acid mixture, is carried out in an expander. 
Postupak prema zahtjevu 6, naznačeno time da je toplinska obrada mješavine životinjske hrane, koja sadrži mješavinu masnih kiselina, izvedena u ekspanderu, poželjno u prisutnosti emulgatora.
wherein the first electrically conductive pad and the thermal pad are thermally and electrically bonded to a first top surface of the outer electrically conductive member without use of a printed circuit board and the second electrically conductive pad is electrically bonded to a second top surface of the inner electrically conductive member. 
pri čemu su prva električno provodna podloga (6) i termička podloga toplotno i električno spojene na prvu gornju površinu električno provodnog elementa bez upotrebe štampane ploče i druga električno provodna podloga (7) je električno spojena na drugi električno provodan element, pri čemu taj aparat za osvjetljenje obuhvata bljeskalicu i spoljnje kućište napravljeno od cijevi (1) bljeskalice.
Power up and start non-operating part of “on” cycle. 
Uključivanje napajanja 1 početak neradnog dijela ciklusa "uključenje".
characterized in that the anode (2) is composed of Fe, Cu, Ni and Sn, wherein the content of Fe is 23-40wt%, the content of Cu is 36-60wt%, the content of Ni is 14-28wt% and the content of Sn is 0.2-5wt%. 
naznačena time da anoda (2) je sačinjena od Fe, Cu, Ni i Sn, gdje sadržaj Fe je 23-40m%, sadržaj Cu je 36- 60m%, sadržaj Ni je 14-28m% i sadržaj Sn je 0.2-5m%.
The method according to any one of claims 12 or 13, wherein step v) is performed by gently adding the further suspension provided in step iv) to the mixture obtained in step iii) to obtain the alcohol-in-oil type emulsion. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 13 ili 14, gdje korak v) se provodi opreznim dodavanjem dodatne suspenzije dodane u koraku iv) u smjesu dobivenu u koraku iii) kako bi se dobilo emulziju tipa alkohol-u-ulju.
A pharmaceutical composition according to claims 1-18, for use for the treatment of acute pain related to the following conditions: headache, toothache, inflammations and migraine. 
Farmaceutski pripravak prema patentnim zahtjevima 1-18, za upotrebu za liječenje akutne boli povezane sa HR P20180974 T1 sljedećim stanjima: glavobolja, zubobolja, upale i migrena.